Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $58.20.

Several research analysts have commented on the stock. Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. HC Wainwright lifted their price objective on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, February 28th.

Insider Activity at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 9,102 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the sale, the chief executive officer now directly owns 115,920 shares in the company, valued at approximately $5,589,662.40. The trade was a 7.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Peter Radovich sold 2,627 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94. Following the completion of the sale, the chief operating officer now directly owns 26,961 shares of the company’s stock, valued at $1,300,059.42. This trade represents a 8.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 133,679 shares of company stock valued at $6,007,081 over the last 90 days. 22.87% of the stock is owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in MIRM. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 46.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 67,375 shares of the company’s stock worth $2,628,000 after buying an additional 21,526 shares during the period. Intech Investment Management LLC purchased a new position in Mirum Pharmaceuticals in the 3rd quarter worth approximately $497,000. Charles Schwab Investment Management Inc. increased its stake in Mirum Pharmaceuticals by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock worth $12,798,000 after purchasing an additional 17,149 shares during the period. Loomis Sayles & Co. L P purchased a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at approximately $19,473,000. Finally, FORA Capital LLC bought a new position in shares of Mirum Pharmaceuticals in the third quarter worth approximately $399,000.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $46.08 on Tuesday. The stock has a fifty day moving average of $48.03 and a 200-day moving average of $43.82. The stock has a market cap of $2.26 billion, a PE ratio of -22.81 and a beta of 1.04. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals has a fifty-two week low of $23.14 and a fifty-two week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $99.41 million during the quarter, compared to analysts’ expectations of $96.64 million. Equities research analysts anticipate that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.